Cardiovascular Department, Guys and St Thomas' Hospital, 6th Floor, East Wing, Westminster Bridge Road, London, SE1 7EH, UK,
Clin Res Cardiol. 2014 Jun;103(6):417-29. doi: 10.1007/s00392-013-0653-3. Epub 2014 Jan 21.
Transcatheter aortic valve implantation has established itself as an alternative treatment for patients with valvular disease. In the current context of increasing bioprosthetic valve implants and an ageing population with growing comorbidities, a less invasive approach to the treatment of bioprosthetic dysfunction would be an appealing alternative to the standard of care. Transcatheter valve-in-valve implantation could be an alternative for patients who are deemed to be a high surgical risk. The valve-in-valve procedure is a minimally invasive percutaneous procedure where a valve can be implanted directly within a failing bioprosthetic valve. This technique can be applied to dysfunctional aortic bioprosthetic valves and can also be used in the pulmonary and atrioventricular valve bioprosthesis. We review the current literature to assess whether this technique may be the new standard for degenerated bioposthesis.
经导管主动脉瓣植入术已成为瓣膜疾病患者的一种替代治疗方法。在目前生物瓣假体植入不断增加以及合并症不断增加的老年人群体中,对于生物瓣功能障碍的这种微创治疗方法可能是一种有吸引力的替代标准治疗方法。对于那些被认为具有高手术风险的患者,经导管瓣中瓣植入术可能是一种替代方法。瓣中瓣手术是一种微创经皮手术,可在功能障碍的生物瓣假体中直接植入一个瓣膜。这项技术可以应用于功能障碍的主动脉生物瓣假体,也可以用于肺动脉瓣和房室瓣生物瓣假体。我们对现有文献进行了回顾,以评估该技术是否可能成为退行性生物瓣假体的新标准。